Literature DB >> 10735269

Oxidative phosphorylation defects and Alzheimer's disease.

J M Shoffner1.   

Abstract

Abnormalities in cellular bioenergetics have been identified in patients with Alzheimer's disease (AD) as well as in patients with other neurodegenerative diseases. The most commonly reported enzyme abnormalities are in the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and oxidative phosphorylation (OXPHOS). Although genetic evidence supporting primary OXPHOS defects as a cause for AD is weak, functionally important reductions in OXPHOS enzyme activities appear to occur in AD and may be related to beta-amyloid accumulation or other neurodegenerative processes. Since reduced neuronal ATP may enhance susceptibility to glutamate toxicity, OXPHOS defects could play an important role in the pathophysiology of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10735269     DOI: 10.1007/s100480050002

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  20 in total

1.  Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release.

Authors:  A M Aleardi; G Benard; O Augereau; M Malgat; J C Talbot; J P Mazat; T Letellier; J Dachary-Prigent; G C Solaini; R Rossignol
Journal:  J Bioenerg Biomembr       Date:  2005-08       Impact factor: 2.945

2.  Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein.

Authors:  Shaohui Huang; Ahmed A Heikal; Watt W Webb
Journal:  Biophys J       Date:  2002-05       Impact factor: 4.033

3.  Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage.

Authors:  Maria Manczak; Byung S Park; Youngsin Jung; P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 4.  Mitochondrial mechanisms of estrogen neuroprotection.

Authors:  James W Simpkins; Kun Don Yi; Shao-Hua Yang; James A Dykens
Journal:  Biochim Biophys Acta       Date:  2009-11-26

Review 5.  Mechanisms of islet amyloidosis toxicity in type 2 diabetes.

Authors:  Andisheh Abedini; Ann Marie Schmidt
Journal:  FEBS Lett       Date:  2013-01-18       Impact factor: 4.124

Review 6.  Estrogen actions on mitochondria--physiological and pathological implications.

Authors:  James W Simpkins; Shao-Hua Yang; Saumyendra N Sarkar; Virginia Pearce
Journal:  Mol Cell Endocrinol       Date:  2008-05-02       Impact factor: 4.102

Review 7.  Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease.

Authors:  Chris Cadonic; Mohammad Golam Sabbir; Benedict C Albensi
Journal:  Mol Neurobiol       Date:  2015-11-04       Impact factor: 5.590

8.  Protective effects of compound FLZ, a novel synthetic analogue of squamosamide, on beta-amyloid-induced rat brain mitochondrial dysfunction in vitro.

Authors:  Fang Fang; Geng-tao Liu
Journal:  Acta Pharmacol Sin       Date:  2009-05       Impact factor: 6.150

Review 9.  Mitochondrial Dysfunction and Mitophagy Closely Cooperate in Neurological Deficits Associated with Alzheimer's Disease and Type 2 Diabetes.

Authors:  Sangita Paul; Debarpita Saha; Binukumar Bk
Journal:  Mol Neurobiol       Date:  2021-04-01       Impact factor: 5.590

10.  Machine learning compensates fold-change method and highlights oxidative phosphorylation in the brain transcriptome of Alzheimer's disease.

Authors:  Jack Cheng; Hsin-Ping Liu; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.